Canvaxin

a polyvalent vaccine immunotherapy for melanoma of three viable irradiated melanoma cell lines which contain at least 11 known tumor-associated antigens such as MAGE-1, MAGE-3, tyrosinase, gp100, gp75, and Mart-1/Melan-A; increased IgM response in patients receiving vaccine therapy for stage II melanoma was associated with decreased recurrence and improved survival

Networked: 13 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Morton, Donald L: 10 articles (02/2012 - 08/2002)
2.	Essner, Richard: 5 articles (11/2007 - 08/2002)
3.	Hsueh, Eddy C: 4 articles (10/2004 - 10/2002)
4.	Hoon, Dave S B: 3 articles (02/2012 - 10/2002)
5.	Ye, Xing: 3 articles (11/2007 - 12/2002)
6.	Gupta, Rishab K: 3 articles (01/2003 - 08/2002)
7.	Foshag, Leland J: 3 articles (12/2002 - 08/2002)
8.	O'Day, Steven J: 3 articles (12/2002 - 08/2002)
9.	Faries, Mark B: 2 articles (02/2012 - 01/2005)
10.	Wang, He-Jing: 2 articles (02/2012 - 10/2002)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 10/01/2004 - "This finding will be evaluated in a multicenter phase III trial of Canvaxin plus bacille Calmette-Guerin (BCG) versus placebo plus BCG after resection of stage III melanoma." 12/20/2005 - "Nineteen of 63 metastatic melanoma patients received Canvaxin pre- and postoperatively, and 37 patients received only postoperative Canvaxin. " 10/01/2002 - "In 1984, the authors began phase II trials of Canvaxin PV as postsurgical adjuvant therapy for AJCC stage III melanoma. " 10/01/2004 - "In vitro cellular immune response to Canvaxin cells directly correlates with survival after subsequent initiation of immunotherapy for AJCC stage III melanoma. " 02/01/2004 - "Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer."
2.	Neoplasms (Cancer) 02/01/2004 - "Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax." 10/01/2004 - "We randomly selected 54 patients from a study of Canvaxin therapy after complete resection of American Joint Committee on Cancer (AJCC) stage III melanoma. " 03/01/2016 - "A polyvalent therapeutic cancer cell vaccine containing three viable, irradiated, replication-incompetent melanoma cell lines (Canvaxin) was administered to over 2500 patients in various clinical studies. " 10/01/2002 - "To determine whether adjuvant postoperative active specific immunotherapy with a therapeutic polyvalent vaccine (PV) called Canvaxin can prolong survival following complete resection of melanoma metastatic to regional nodes (American Joint Committee on Cancer [AJCC] stage III melanoma). " 02/01/2004 - "CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. "
3.	Colonic Neoplasms (Colon Cancer) 02/01/2004 - "Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer." 02/01/2004 - "CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. "
4.	Disease Progression 01/01/2004 - "Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma."
5.	Hypersensitivity (Allergy) 01/01/2004 - "In 77 patients who received Canvaxin vaccine after resection of stage IV melanoma, five-year OS rate was 75% for patients with an elevated level of IgM antibodies against a 90-kD glycoprotein antigen (TA90) expressed by the vaccine, and a strong delayed-type hypersensitivity (DTH) response to the vaccine; by contrast, survival was 36% for patients who had either an elevated IgM response or a strong DTH response, and only 8% if neither response was strong (P < .001). "

Related Drugs and Biologics

1.	polyvalent melanoma cell vaccine
2.	Vaccines
3.	Cancer Vaccines
4.	Combined Vaccines
5.	Antigens
6.	Glycoproteins (Glycoprotein)
7.	Antibodies
8.	Immunoglobulin M (IgM)
9.	Neoplasm Antigens (Tumor Antigens)

Related Therapies and Procedures

1.	Immunotherapy
2.	Cytoreduction Surgical Procedures
3.	Therapeutics
4.	Metastasectomy